Opinion|Videos|December 24, 2024
New and Upcoming Therapies in Atopic Dermatitis
Author(s)James Song, MD, FAAD
James Song, MD, FAAD, discusses how recent advancements in atopic dermatitis treatment include targeted biologics and Janus kinase inhibitors that offer promising alternatives to traditional therapies for patients with moderate-to-severe disease.
Advertisement
Episodes in this series
Advertisement
Related to this article
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Oral PKM2 Modulator Shows Early Efficacy in Atopic Dermatitis
2
Alopecia Areata Is a Medical Disease: Treatment Options and Defining Severity
3
Galderma to Acquire ZO Skin Health for $1.5 Billion
4
Chronic Hand Eczema Linked to Lost Productivity and Lower Quality of Life
5